Vidac Pharma Holding Plc logo

Vidac Pharma Holding Plc (T9G)

Market Closed
25 Jul, 20:00
XSTU XSTU
0. 48
+0
+0.42%
- Market Cap
- P/E Ratio
0% Div Yield
57,261 Volume
- Eps
0.48
Previous Close
Day Range
0.48 0.51
Year Range
0.2 1.3
Want to track T9G and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

T9G closed today higher at €0.48, an increase of 0.42% from yesterday's close, completing a monthly decrease of -3.21% or €0.02. Over the past 12 months, T9G stock lost -31.14%.
T9G is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XSTU (EUR).

T9G Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.

Vidac Pharma Holding Plc Dividends

T9G is not paying dividends to its shareholders.

Vidac Pharma Holding Plc Earnings

T9G have yet to publish their earning reports.
T9G is not paying dividends to its shareholders.
T9G have yet to publish their earning reports.

Vidac Pharma Holding Plc (T9G) FAQ

What is the stock price today?

The current price is €0.48.

On which exchange is it traded?

Vidac Pharma Holding Plc is listed on XSTU.

What is its stock symbol?

The ticker symbol is T9G.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, no market cap data is available.

Has Vidac Pharma Holding Plc ever had a stock split?

No, there has never been a stock split.

Vidac Pharma Holding Plc Profile

- Industry
- Sector
- CEO
XSTU Exchange
- ISIN
United Kingdom Country
- Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Vidac Pharma Holding Plc operates as an investment holding company primarily focused on the discovery and development of pharmaceutical treatments targeting oncologic (cancer-related) and dermatologic diseases. Founded in 2021 with its headquarters situated in London, United Kingdom, the company leverages its expertise to develop innovative therapies that address significant unmet medical needs in the oncology and dermatology sectors. Through its dedication to research and development, Vidac Pharma aims to bring forth new options for patients battling life-threatening diseases by targeting the disease at its source with minimal impact on healthy cells.

Products and Services

  • VDA-1102 Ointment

    This anti-neoplastic agent is currently under Phase 2 clinical trials. VDA-1102 ointment is designed to induce apoptosis (programmed cell death) specifically in cancer cells, while limiting the effects on surrounding healthy cells. Its unique mechanism makes it potentially beneficial for treating a wide variety of cancers with fewer side effects compared to traditional treatments.

  • VDA-1102 IV

    An intravenous formulation of the VDA-1102, this anti-neoplastic agent shares the same goal of triggering apoptosis in cancer cells but is suitable for conditions or tumor types that may not be effectively treated with a topical application. This variation of VDA-1102 is still in the development phase, focusing on broadening the application of Vidac Pharma's apoptosis-inducing technology to a wider range of cancers.

  • VDA-1275

    This is a potent small molecule and new chemical entity in the preclinical stage, developed by Vidac Pharma for the treatment of solid tumors. VDA-1275 represents the company's commitment to expanding its oncology portfolio by exploring more targeted and efficient ways to combat cancer, potentially improving outcomes for patients with solid tumors.

Contact Information

Address: 20-22, Wenlock Road
Phone: 972 54 4257381